The Technical Analyst
Select Language :
Bicycle Therapeutics PLC [BCYC]

Exchange: NasdaqGS Sector: Healthcare Industry: Biotechnology

Bicycle Therapeutics PLC Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

Bicycle Therapeutics PLC is listed at the NASDAQ Exchange

4.23% $17.49

Last updated: 3 jul 2022 - 19:56

TimeZone: America/New_York


FUNDAMENTALS
MarketCap: 518.55 mill
EPS: -2.91
P/E: 0.000
Earnings Date: Aug 03, 2022
SharesOutstanding: 29.65 mill
Avg Daily Volume: 0.663 mill
RATING 2022-07-01
B+
Buy
RATINGDETAILS
Rating CashFlow: Strong Buy
Return On Equity: Neutral
Return On Asset: Neutral
DE: Neutral
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
4/201/212/213/214/211/22
Revenue
Gr.Profitn/an/an/an/an/an/a
Ebit
Asset
Debt
DISCOUNTED CASH FLOW VALUE
$34.99
(100.08%) $17.50
Date: 2022-07-03
True Range Average
+/- $1.538
( +/- 8.79%)
Range: 15.95 - 19.03
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2022-03-25 Milnes Alistair Buy 5 155 Employee Stock Option (right to buy)
2022-03-25 Milnes Alistair Buy 5 155 Ordinary Shares
2022-01-03 Jordan Veronica Gh Buy 10 000 Stock Option (right to buy)
2022-01-03 Jordan Veronica Gh Buy 5 000 Ordinary Shares
2022-01-03 Winter Gregory Paul Buy 10 000 Stock Option (right to buy)
INSIDER POWER
21.69
Last 100 transactions
Buy: 886 197 | Sell: 585 669

Forecast: 16:00 - $17.49

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $17.49
Forecast 2: 16:00 - $17.49
Forecast 3: 16:00 - $17.49
SCORE
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $17.49 (4.23% )
Volume 0.142 mill
Avg. Vol. 0.663 mill
% of Avg. Vol 21.46 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Bicycle Therapeutics PLC

Last 12 Months

Last 12 months chart data with high, low, open and close for Bicycle Therapeutics PLC

RSI

Intraday RSI14 chart for Bicycle Therapeutics PLC

Last 10 Buy & Sell Signals For BCYC

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since 31-12-69

Date Signal @ Closed %
Jun 28 - 16:58sell$17.00N/AActive
The Live Chart for Bicycle Therapeutics PLC
Profile picture for
            Bicycle Therapeutics PLC

BCYC

Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. The company is headquartered in Cambridge, Cambridgeshire and currently employs 61 full-time employees. The firm is focused on developing a class of medicines for diseases. The Company’s lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) for oncology indications. BT1718 targets tumors that express Membrane Type 1 matrix metalloprotease (MT1-MMP). The firm is also developing BT5528 and BT8009, which are BTCs targeting Ephrin type-A receptor 2 (EphA2), and Nectin-4, for oncology indications. The firm is also developing cytotoxic T-cell activators, designed to trigger an immune response to tumors.

Last 10 Buy Signals
Date Signal @
BNTUSDJul 3 - 19:540.488
DCRUSDJul 3 - 19:5422.62
LINKUSDJul 3 - 19:546.20
BLOCKUSDJul 3 - 19:510.183
ARKUSDJul 3 - 19:490.423
MAIDUSDJul 3 - 19:480.184
GAMEUSDJul 3 - 19:480.0152
UBQUSDJul 3 - 19:480.0337
LSKUSDJul 3 - 19:471.030
DOGEUSDJul 3 - 19:46$0.0671

Stock Peers

Company Price Change
BCYC17.494.23%
AURA14.210.28%
CPSI32.461.53%
GERN1.6707.74%
GHRS10.151.70%
IPSC8.794.64%
PETQ17.715.48%
SIBN13.603.03%
STOK13.774.24%
TCDA9.64-0.41%
TNGX4.754.86%

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.